Prognostic and Predictive Value of Circulating Inflammation Signature in Non-Metastatic Nasopharyngeal Carcinoma: Potential Role for Individualized Induction Chemotherapy

References

• Chen Y, Chan A, Le Q, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (Lond). 2019;394(10192):64–80. doi:10.1016/S0140-6736(19)30956-0
   PubMed Web of Science ®Google Scholar
• Mao Y-P, Xie F-Y, Liu L, et al. Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging. Int J Radiat Oncol Biol Phys. 2009;73(5):1326–1334. doi:10.1016/j.ijrobp.2008.07.062
   PubMed Web of Science ®Google Scholar
• Chen Y-P, Tang L-L, Yang Q, et al. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Clin Cancer Res. 2018;24(8):1824–1833. doi:10.1158/1078-0432.CCR-17-2656
   PubMed Web of Science ®Google Scholar
• Chua DT, Ma J, Sham JS, et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two Phase III trials. J Clin Oncol. 2005;23(6):1118–1124. doi:10.1200/JCO.2005.12.081
   PubMed Web of Science ®Google Scholar
• Hong R, Hsiao C, Ting L, et al. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study. Ann Oncol. 2018;29(9):1972–1979. doi:10.1093/annonc/mdy249
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network Head and Neck Cancers, version 2.2021 — march 26, 2021. Available from: http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed April 20, 2021.
   Google Scholar
• Lei Y, Li Y, Jiang W, et al. A gene-expression predictor for efficacy of induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2021;113(4):471–480. doi:10.1093/jnci/djaa100
   PubMedGoogle Scholar
• Peng H, Chen L, Li W, et al. Tumor response to neoadjuvant chemotherapy predicts long-term survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma: a secondary analysis of a randomized Phase 3 clinical trial. Cancer. 2017;123(9):1643–1652. doi:10.1002/cncr.30520
   PubMed Web of Science ®Google Scholar
• ML Disis. Immune regulation of cancer. J Clin Oncol. 2010;28(29):4531–4538.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Shinko D, Diakos CI, Clarke SJ, Charles KA. Cancer-related systemic inflammation: the challenges and therapeutic opportunities for personalized medicine. Clin Pharmacol Ther. 2017;102(4):599–610. doi:10.1002/cpt.789
   PubMed Web of Science ®Google Scholar
• Varkaris A, K A, Davis JS, et al. Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. Br J Cancer. 2019;120(3):340–345. doi:10.1038/s41416-018-0360-y
   PubMed Web of Science ®Google Scholar
• A Mantovani, P Allavena, A Sica,et al. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Li W, Hua X, Lv S, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for de novo metastatic nasopharyngeal carcinoma. J Inflamm Res. 2021;14:817–828. doi:10.2147/JIR.S296710
   PubMed Web of Science ®Google Scholar
• Tang LQ, Li CF, Li J, et al. Establishment and validation of prognostic nomograms for endemic nasopharyngeal carcinoma. J Natl Cancer Inst. 2016;108(1).
   Google Scholar
• Li JP, Chen SL, Liu XM, et al. A novel inflammation-based stage (I stage) predicts overall survival of patients with nasopharyngeal carcinoma. Int J Mol Sci. 2016;17(11):1900.
   Web of Science ®Google Scholar
• Xia X, Zhang H-B, Shi J-L, et al. A prognostic model predicts the risk of distant metastasis and death for patients with nasopharyngeal carcinoma based on pre-treatment serum C-reactive protein and N-classification. Eur J Cancer. 2013;49(9):2152–2160. doi:10.1016/j.ejca.2013.03.003
   PubMed Web of Science ®Google Scholar
• Yang S, Zhao K, Ding X, Jiang H, Lu H. Prognostic Significance of hematological markers for patients with nasopharyngeal carcinoma: a meta-analysis. J Cancer. 2019;10(11):2568–2577. doi:10.7150/jca.26770
   PubMed Web of Science ®Google Scholar
• Lu A, Li H, Zheng Y, et al. Prognostic significance of neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio, and platelet to lymphocyte ratio in patients with nasopharyngeal carcinoma. Biomed Res Int. 2017;2017:3047802.
   PubMed Web of Science ®Google Scholar
• Li W, Lv S, Liu G, et al. Development of a prognostic model to identify the suitable definitive radiation therapy candidates in de novo metastatic nasopharyngeal carcinoma: a Real-World Study. Int J Radiat Oncol Biol Phys. 2021;109(1):120–130. doi:10.1016/j.ijrobp.2020.08.045
   PubMed Web of Science ®Google Scholar
• Yao -J-J, Zhu F-T, D J, et al. Prognostic value of neutrophil-to-lymphocyte ratio in advanced nasopharyngeal carcinoma: a large institution-based cohort study from an endemic area. BMC Cancer. 2019;19(1):37. doi:10.1186/s12885-018-5236-2
   PubMedGoogle Scholar
• Li X-H, C H, Xu B-Q, et al. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Cancer Med. 2017;6(1):310–319. doi:10.1002/cam4.947
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 2018;14(5):549–556. doi:10.7150/ijbs.24374
   PubMed Web of Science ®Google Scholar
• Peng H, Dong D, Fang M-J, et al. Prognostic value of deep learning PET/CT-based radiomics: potential role for future individual induction chemotherapy in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2019;25(14):4271–4279. doi:10.1158/1078-0432.CCR-18-3065
   PubMed Web of Science ®Google Scholar
• Zhang B, Tian J, Dong D, et al. Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2017;23(15):4259–4269. doi:10.1158/1078-0432.CCR-16-2910
   PubMed Web of Science ®Google Scholar
• Zhang B, He X, Ouyang F, et al. Radiomic machine-learning classifiers for prognostic biomarkers of advanced nasopharyngeal carcinoma. Cancer Lett. 2017;403:21–27. doi:10.1016/j.canlet.2017.06.004
   PubMed Web of Science ®Google Scholar
• Bodelon C, Polley MY, Kemp TJ, et al. Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol. 2013;24(8):2073–2079. doi:10.1093/annonc/mdt175
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011;104(4):726–734. doi:10.1038/sj.bjc.6606087
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Matsumura Y, Karube Y, et al. Inflammation-based prognostic score predicts postoperative survival of patients with interstitial pneumonia after undergoing lung cancer resection. World J Surg. 2018;42(7):2143–2152. doi:10.1007/s00268-017-4426-4
   PubMed Web of Science ®Google Scholar
• Wang Y, Qu X, Kam N-W, et al. An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy. BMC Cancer. 2018;18(1):692. doi:10.1186/s12885-018-4513-4
   PubMedGoogle Scholar
• Z H, Ueland PM, U A, et al. Plasma biomarkers of inflammation, the kynurenine pathway, and risks of all-cause, cancer, and cardiovascular disease mortality: the Hordaland Health Study. Am J Epidemiol. 2016;183(4):249–258. doi:10.1093/aje/kwv242
   PubMed Web of Science ®Google Scholar
• Li W, Liu G, Lin L, et al. MRI-detected residual retropharyngeal lymph node after intensity-modulated radiotherapy in nasopharyngeal carcinoma: prognostic value and a nomogram for the pretherapy prediction of it. Radiother Oncol. 2020;145:101–108. doi:10.1016/j.radonc.2019.12.018
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–574. doi:10.1177/0272989X06295361
   PubMed Web of Science ®Google Scholar
• Lam WKJ, Chan KCA, Lo YMD. Plasma Epstein-Barr virus DNA as an archetypal circulating tumour DNA marker. J Pathol. 2019;247(5):641–649. doi:10.1002/path.5249
   PubMed Web of Science ®Google Scholar
• Liu L, Chen Q-Y, Tang L-Q, et al. Neoadjuvant or adjuvant chemotherapy plus concurrent CRT versus concurrent CRT alone in the treatment of nasopharyngeal carcinoma: a study based on EBV DNA. J Natl Compr Canc Netw. 2019;17(6):703–710. doi:10.6004/jnccn.2018.7270
   PubMed Web of Science ®Google Scholar
• Chan C, Ma BBY, Lo YMD, et al. Phase II study of neoadjuvant carboplatin and paclitaxel followed by radiotherapy and concurrent cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: therapeutic monitoring with plasma Epstein-Barr virus DNA. J Clin Oncol. 2004;22(15):3053–3060. doi:10.1200/JCO.2004.05.178
   PubMed Web of Science ®Google Scholar
• Liu L, Tang L-Q, Chen Q-Y, et al. The prognostic value of plasma epstein-barr viral dna and tumor response to neoadjuvant chemotherapy in advanced-stage nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2015;93(4):862–869. doi:10.1016/j.ijrobp.2015.08.003
   PubMed Web of Science ®Google Scholar
• Zhang J, Peng H, Li W-F, et al. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma. BMC Cancer. 2018;18(1):1276. doi:10.1186/s12885-018-5177-9
   PubMedGoogle Scholar
• Xu C, Zhang S, Li W-F, et al. Selection and validation of induction chemotherapy beneficiaries among patients with T3N0, T3N1, T4N0 nasopharyngeal carcinoma using epstein-barr virus DNA: a joint analysis of real-world and clinical trial Data. Front Oncol. 2019;9:1343. doi:10.3389/fonc.2019.01343
   PubMed Web of Science ®Google Scholar
• Li JY, Huang CL, Luo WJ, et al. An integrated model of the gross tumor volume of cervical lymph nodes and pre-treatment plasma Epstein-Barr virus DNA predicts survival of nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: a big-data intelligence platform-based analysis. Ther Adv Med Oncol. 2019;11:1758835919877729.
   Web of Science ®Google Scholar
• Kim K, Le Q-T, Yom SS, et al. Clinical utility of epstein-barr virus DNA testing in the treatment of nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2017;98(5):996–1001. doi:10.1016/j.ijrobp.2017.03.018
   PubMed Web of Science ®Google Scholar
• Nicholls JM, Lee VH-F, Chan S-K, et al. Negative plasma Epstein-Barr virus DNA nasopharyngeal carcinoma in an endemic region and its influence on liquid biopsy screening programmes. Br J Cancer. 2019;121(8):690–698. doi:10.1038/s41416-019-0575-6
   PubMed Web of Science ®Google Scholar
• Le Q-T, Zhang Q, Cao H, et al. An international collaboration to harmonize the quantitative plasma Epstein-Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin Cancer Res. 2013;19(8):2208–2215. doi:10.1158/1078-0432.CCR-12-3702
   PubMed Web of Science ®Google Scholar
• Ma brigette BY, K A, Lo YMD, et al. Relationship between pre-treatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;66(3):714–720. doi:10.1016/j.ijrobp.2006.05.064
   PubMed Web of Science ®Google Scholar
• L J, C Y, Z G, et al. Liquid biopsy tracking during sequential chemoradiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun. 2019;10(1):3941.
   PubMedGoogle Scholar
• Tang L-Q, Li C-F, Chen Q-Y, et al. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study. Int J Radiat Oncol Biol Phys. 2015;91(2):325–336. doi:10.1016/j.ijrobp.2014.10.005
   PubMed Web of Science ®Google Scholar
• Chua melvin LK, Tan SH, K G, et al. Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: a pooled analysis of two randomised controlled trials. Eur J Cancer. 2016;67:119–129. doi:10.1016/j.ejca.2016.08.006
   PubMed Web of Science ®Google Scholar
• Wang Y-Q, Zhang Y, Jiang W, et al. Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis. J Immunother Cancer. 2019;7(1):298. doi:10.1186/s40425-019-0752-4
   PubMed Web of Science ®Google Scholar
• Yp C, Yq W, Jw L, et al. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol. 2019;30(1):68–75.
   PubMed Web of Science ®Google Scholar
• Tang X-R, Li Y-Q, Liang S-B, et al. Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382–393. doi:10.1016/S1470-2045(18)30080-9
   PubMed Web of Science ®Google Scholar
• L N, Chen N-Y, Cui R-X, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–641. doi:10.1016/S1470-2045(12)70102-X
   PubMed Web of Science ®Google Scholar